Global Catheter-Directed Thrombolysis Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, By Application (Deep Vein Thrombosis, Pulmonary Embolism, Ischemic Stroke, Other Applications), By End User (Hospitals, Ambulatory Surgical Centers), By Thrombolytic Technique (Catheter-Directed Thrombolysis (CDT), Pharmacomechanical CDT), By Region, By Company 2021-2031F 2021-2031F

Key Insights	Details
Forecast Period	2026 - 2031
Market Size (2025)	USD 507.79 Million
CAGR (2026-2031)	5.49%
Fastest Growing Segment	Pulmonary Embolism (led with 41.02% share in 2025)
Largest Market	North America
Market Size (2031)	USD 699.76 Million

Market Overview

The Global Catheter-Directed Thrombolysis Market is expected to grow from USD 507.79 Million in 2025 to USD 699.76 Million by 2031 at a 5.49% CAGR. Catheter-directed thrombolysis (CDT) is a minimally invasive endovascular procedure utilizing a catheter and X-ray guidance to deliver targeted medication directly into blood clots, thereby dissolving them to restore blood flow and prevent organ damage. The market growth is primarily driven by the increasing global prevalence of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, along with continuous advancements in catheter technology that enhance procedural efficacy and patient outcomes. According to the American Heart Association's 2025 statistical update, pulmonary embolism, a primary indication for this procedure, sends over 500,000 individuals to U.S. hospitals each year.

However, a significant challenge impeding market expansion involves the inherent risk of bleeding complications associated with thrombolytic agents. These risks necessitate careful patient selection and monitoring, which can limit the broader applicability of CDT, particularly in patients with higher susceptibility to hemorrhage, thus constraining wider adoption across diverse clinical scenarios.

Key Market Drivers

Rising thromboembolic disease burden drives CDT demand
The global catheter-directed thrombolysis market is significantly propelled by the increasing worldwide prevalence of thromboembolic disorders, including deep vein thrombosis and pulmonary embolism. These conditions necessitate effective and rapid interventions to prevent severe complications, thereby fueling the demand for advanced treatment modalities like catheter-directed thrombolysis. The rising incidence places a substantial burden on healthcare systems globally, driving the need for more efficient and targeted therapies. According to the American Heart Association's 2026 Heart Disease and Stroke Statistics, approximately 470,000 people are hospitalized with pulmonary embolism in the U.S. annually, underscoring the persistent and high volume of patients requiring treatment. This considerable patient population directly translates into a sustained demand for catheter-directed thrombolysis procedures.

Technological advances and industry activity strengthen CDT's market outlook
Technological advancements in catheter-directed thrombolysis further bolster market expansion by enhancing procedural safety and efficacy. Innovations focus on developing more precise catheter designs, improved drug delivery systems, and devices that minimize complications, attracting a broader patient base and encouraging physician adoption. These technological refinements aim to reduce treatment times and improve patient outcomes. For instance, in October 2026, Endovascular Engineering announced its Hēlo Blood Return System, cleared by the FDA, reduced median blood loss by 97% in the ENGULF trial, highlighting significant improvements in patient safety. This continuous innovation contributes to the growing confidence in CDT as a viable and effective treatment option. The strategic importance of this sector is also reflected in notable industry activities; according to Vascular News, in January 2026, Boston Scientific agreed to acquire Penumbra for approximately US$14.5 billion, signaling substantial investment and confidence in companies developing thrombectomy solutions.

Download Free Sample Report

Key Market Challenges

Bleeding Risk Limits Adoption and Market Growth
The inherent risk of bleeding complications associated with thrombolytic agents represents a significant challenge for the global catheter-directed thrombolysis market. This critical concern mandates rigorous patient selection and continuous monitoring, thereby limiting the broader application of catheter-directed thrombolysis, especially in individuals predisposed to hemorrhage. Such restrictions inherently constrain the widespread adoption of this procedure across various clinical settings, directly impeding market growth by reducing the eligible patient population.

Inconsistent Guidance Hinders Risk Stratification and Procedure Uptake
The complexity of balancing therapeutic benefits against bleeding risks also contributes to inconsistent clinical practice. According to the 'Get Out the Clot' campaign survey, published in September 2025 by a collaboration of medical societies including the International Society on Thrombosis and Haemostasis and the Society for Vascular Medicine, only 56% of interventional physicians surveyed believe their protocols provide clear direction for pulmonary embolism risk beyond medical management. This lack of standardized guidance highlights the ongoing difficulty in risk stratification and treatment decision-making, resulting in varied approaches that deter a consistent increase in catheter-directed thrombolysis procedure volumes.

Key Market Trends

Personalized Medicine in Thrombolysis: Market and Treatment Implications
Personalized medicine approaches in thrombolysis are significantly shaping the global market by optimizing treatment strategies for individual patient profiles. This trend involves leveraging genetic and biomarker data to predict patient response to thrombolytic agents, thereby improving efficacy and minimizing bleeding risks. Such tailored interventions lead to more precise drug dosing and targeted delivery, enhancing overall patient outcomes and expanding the applicability of catheter-directed thrombolysis. For instance, according to touchNEUROLOGY, May 2026, in "ESOC 2026 highlights: Personalized thrombectomy strategies and neuroprotection reshape stroke care," the HOPE trial, which explored tailoring systolic blood pressure targets after endovascular thrombectomy for acute ischemic stroke, enrolled 440 patients across 11 stroke centers in Spain.

Outpatient Adoption of CDT for DVT in Ambulatory Surgical Centers
The increasing utilization of ambulatory surgical centers for elective deep vein thrombosis cases represents a transformative trend driven by the pursuit of cost-efficiency and enhanced patient convenience. This migration from traditional inpatient hospital settings to outpatient facilities reduces healthcare expenditures and shortens hospital stays, making CDT more accessible. Regulatory adjustments are actively supporting this shift, paving the way for a broader range of procedures to be performed in these settings. According to Becker's ASC Review, September 2026, in "The procedures that shifted to the outpatient model in 2026," more than 500 procedures became newly eligible for the outpatient or ambulatory surgical center setting in a single year.

Segmental Insights

Pulmonary Embolism Emerges as Leading Segment with 41.02% Share, Fueled by Aging Population and Catheter Innovations
Pulmonary Embolism emerged as the leading segment in the Global Catheter-Directed Thrombolysis Market, securing a 41.02% share in 2025. This rapid growth is primarily attributed to the increasing incidence of venous thromboembolism, including life-threatening pulmonary embolism cases, across an aging global population. Furthermore, advancements in catheter technology enable targeted drug delivery with reduced systemic exposure, thereby enhancing treatment efficacy and safety while minimizing bleeding complications. The increasing adoption of minimally invasive procedures, offering shorter recovery times and improved patient outcomes compared to traditional systemic thrombolysis, significantly drives this segment's expansion. Growing awareness and clinical endorsement by institutions like the American Heart Association for catheter-based interventions for acute pulmonary embolism further contribute to its dominant market position.

Regional Insights

North America Leads Market Driven by Infrastructure, Coverage, and Regulatory Support
North America leads the global catheter-directed thrombolysis market due to its robust healthcare infrastructure and well-established interventional radiology networks. The region benefits from broad insurance coverage and advantageous reimbursement policies, notably those implemented by the Centers for Medicare & Medicaid Services, which financially support the adoption of advanced procedures. Furthermore, a high prevalence of thrombotic disorders, such as deep vein thrombosis and pulmonary embolism, drives demand for these treatments. Regulatory support from bodies like the U.S. Food and Drug Administration, including streamlined clearance processes for devices, also fosters market growth.

Recent Developments

• In July 2025, Inari Medical, operating under Stryker, commercially launched its next-generation InThrill Thrombectomy System. This system is specifically engineered for small vessel and arteriovenous (AV) access thrombectomy, providing capabilities for rapid and complete luminal clot removal. The introduction of the InThrill system strengthens the portfolio of interventional tools available for treating thrombotic events, which can influence and intersect with the catheter-directed thrombolysis market by offering alternative or complementary mechanical clot extraction solutions.
• In June 2025, Inquis Medical achieved a significant milestone by receiving US Food and Drug Administration (FDA) clearance for its Aventus Thrombectomy System. This system is designed for the treatment of pulmonary embolism, incorporating features such as 360-degree directional aspiration and real-time TrueClot tissue sensing. The FDA clearance represents a key new product launch, adding advanced technology to the range of devices available for thrombectomy procedures. This further impacts the global catheter-directed thrombolysis market by providing innovative options for clot removal.
• In December 2024, Flow Medical, a Chicago-based startup, advanced its innovative catheter-directed thrombolysis platform with the presentation of its next-generation thrombolysis catheter prototype. This minimally invasive system is specifically designed for treating pulmonary embolism by using a novel nitinol scaffold to perforate blood clots and precisely deliver thrombolytic drugs. The company secured a $5 million seed funding round in December 2024 to support the continued development of this device. This development represents significant progress in enhancing targeted clot removal strategies within the global catheter-directed thrombolysis market.
• In October 2024, Surmodics announced it had received US Food and Drug Administration (FDA) 510(k) clearance for its Pounce XL thrombectomy system. This regulatory approval facilitates the introduction of a new device intended for the mechanical removal of thrombi, thereby expanding the available treatment options for various thrombotic conditions. The Pounce XL system contributes to the evolving landscape of interventional devices, which either complement or compete with traditional catheter-directed thrombolysis methods for efficient clot management in the global market.

Key Market Players

• Boston Scientific Corporation
• AngioDynamics, Inc.
• Thrombolex
• Medtronic Plc
• Edwards Lifesciences Corporation
• BD (Becton Dickinson)
• Inari Medical
• Penumbra
• Teleflex
• iVascular

By Application	By End User	By Thrombolytic Technique	By Region
Deep Vein Thrombosis Pulmonary Embolism Ischemic Stroke Other Applications	Hospitals Ambulatory Surgical Centers	Catheter-Directed Thrombolysis (CDT) Pharmacomechanical CDT	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Catheter-Directed Thrombolysis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Catheter-Directed Thrombolysis Market, By Application:

• Deep Vein Thrombosis
• Pulmonary Embolism
• Ischemic Stroke
• Other Applications

• Catheter-Directed Thrombolysis Market, By End User:

• Hospitals
• Ambulatory Surgical Centers

• Catheter-Directed Thrombolysis Market, By Thrombolytic Technique:

• Catheter-Directed Thrombolysis (CDT)
• Pharmacomechanical CDT

• Catheter-Directed Thrombolysis Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE